Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteogenomic characterization of pancreatic solid pseudopapillary neoplasm

ABSTRACT: To characterize pancreatic solid pseudopapillary neoplasm at protein level, we performed mass spectromery-based proteome analysis using clinical FFPE tissue samples.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell, Pancreas

DISEASE(S): Pancreatic Solid Pseudopapillary Carcinoma

SUBMITTER: Atsushi Tanaka

LAB HEAD: Michael Roehrl,

PROVIDER: PXD039182 | Pride | 2025-09-16

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	N1.raw	Raw
	N2.raw	Raw
	N3.raw	Raw
	N4.raw	Raw
	N5.raw	Raw

Items per page:

1 - 5 of 46

Similar Datasets

Proteogenomic characterization of metastatic colorectal cancer with its primary origin

Project description:To characterize metastatic progression of colorectal cancer, we performed mass spectromery-based proteome analysis using clinical samples.

2024-01-16 | PXD034575 | Pride

Proteogenomic characterization of pancreatic acinar cell carcinoma and pancreatoblastoma

Project description:To characterize pancreatic cancer with acinar differentiation at protein level, we performed mass spectromery-based proteome analysis using clinical FFPE tissue samples.

2024-09-17 | PXD036998 | Pride

Proteogenomic characterization of pancreatic neuroendocrine tumor

Project description:To characterize pancreatic neuroendocrine tumor at protein level, we performed mass spectromery-based proteome analysis using clinical FFPE tissue samples.

2024-07-10 | PXD034571 | Pride

MicroRNA profiling of tumor and stromal tissue in metastatic colorectal paitents

Project description:Specific MicroRNAs (miRNAs) have been found up- or down-regulated in colorectal cancer, and they are associated with prognosis or response to chemotherapy or targeted drugs. The microenvironment close to the neoplasm plays a leading role in tumor spread and survival. We used microarray technology to profile miRNA expression both in primary tumor and stromal tissue to study differences and clinical implications.

2014-11-04 | E-MTAB-2479 | biostudies-arrayexpress

RNA-seq of FFPE-macrodissected HGSOC tissues and solid and ascites-derived HGSOC 2D cultures

Project description:Stratification of a retrospective cohort of HGSOC based on its tissues of origin.

2020-09-29 | E-MTAB-9605 | biostudies-arrayexpress

Transcritional profiling in 30 follicular cell derived thyroid cancers

Project description:We established transcriptional profiles by microarray in a small series of follicular cell derived thyroid cancers collected at our Institute. This series comprises 27 papillary thyroid carcinomas (PTCs), the most common type of thyroid cancer, and 3 poorly differentiated thyroid carcinomas (PDTCs). Two patient matched non-neoplastic thyroids are also included as controls.

2024-07-27 | E-MTAB-13222 | biostudies-arrayexpress

Steroids-producing adrenocortical nodules (bulk RNA-seq)

Project description:This data was used in the analysis of the article titled ‘Steroids-producing adrenocortical nodules: a novel two-layered structure as a precursor lesion of cortisol-producing adenoma’.

2023-07-20 | E-MTAB-13109 | biostudies-arrayexpress

Profiling of pancreatic adenocarcinoma using artificial intelligence-based integration of multi-omic and computational pathology features

Project description:Contemporary analyses focused on a limited number of clinical and molecular features have been unable to accurately predict clinical outcomes in pancreatic ductal adenocarcinoma (PDAC). Here we describe a novel, conceptual approach and use it to analyze clinical, computational pathology, and molecular (DNA, RNA, protein, and lipid) analyte data from 74 patients with resectable PDAC. Multiple, independent, machine learning models were developed and tested on curated singleand multi-omic feature/analyte panels to determine their ability to predict clinical outcomes in patients. The multi-omic models predicted recurrence with an accuracy and positive predictive value (PPV) of 0.90, 0.91, and survival of 0.85, 0.87, respectively, outperforming every singleomic model. In predicting survival, we defined a parsimonious model with only 589 multi-omic analytes that had an accuracy and PPV of 0.85. Our approach enables discovery of parsimonious biomarker panels with similar predictive performance to that of larger and resource consuming panels and thereby has a significant potential to democratize precision cancer medicine worldwide.

2024-01-23 | PXD037038 | Pride

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Adults with fusions associated with Ph-like ALL

Project description:Allogenic hematopoietic cell transplantation (alloHCT) is a well-established curative modality for adults with high-risk ALL; yet large data describing alloHCT outcomes in Philadelphia (Ph)-like ALL is lacking. We retrospectively analyzed archived DNA samples from consecutive adults with B-cell Ph-negative ALL who underwent alloHCT in complete remission (CR) (n= 127) at our center between 2006 and 2020. Identification of fusions associated with Ph-like were performed using accumulative results from RNAseq, conventional cytogenetics, FISH, and whole genome array studies. Fusions associated with Ph-like were detected in 56 (44%) patients, of whom 38 were carrying CRLF2r; and the rest (n=18) were non-CRLF2r. Compared to other non-Ph-like (n=71), patients with fusions associated with Ph-like ALL were more frequently Hispanic (P=0.008), less frequently carried high-risk cytogenetics (P<0.001), and more likely to receive blinatumomab prior to HCT (P=0.019). With the median follow-up of 3.5 years, patients with Ph-like ALL fusions had comparable post-transplant outcomes compared to other B-cell ALL: 3-year relapse-free survival (RFS) [41% vs. 44%, P=0.36], overall survival (OS) [51% vs. 50%, P=0.59] and relapse [37% vs. 31%, P=0.47]. In multivariable analysis, age (P= 0.023), disease status at the time of transplant (P<0.001), and donor type (P=0.015) influenced OS. RFS (primary endpoint) was significantly influenced by disease status (P<0.001) and conditioning regimen intensity (P=0.014). Relapse rate was associated with disease status (P=0.028) and conditioning regimen intensity (P=0.028). In conclusion, our data suggest that alloHCT consolidation results in similarly favorable survival outcomes in adult patients with Ph-like fusions and other high-risk B-cell ALL.

2022-08-01 | E-MTAB-11954 | biostudies-arrayexpress

Four subgroups by gene expression profile correlate with biological and clinical features in colorectal cancer.

Project description:(Purpose) Biological classification of colorectal cancer (CRC) can help to understand its heterogeneous background. The purpose of this study is to classify CRC based on gene expression profiles using formalin-fixed paraffin-embedded (FFPE) samples and to correlate subgroups of CRC with biological features and clinical outcomes. (Results) CRC was clustered into four subgroups by unsupervised hierarchical clustering method. These subgroups show different biological and clinical features. (Conclusion) Gene expression profiles of CRC using FFPE samples distinguish four subgroups that had different biological features and clinical outcomes. These subgroups may explain heterogeneity of CRC and be useful biomarker for clinical. Patients and Methods: One hundred patients with unresectable and advanced or recurrent CRC who underwent the surgical resection from 1998 to 2010 were enrolled in this study. RNA extracted from FFPE samples was subjected to gene expression microarray. After comprehensive gene expression analysis, CRC were classified by an unsupervised hierarchical clustering and a principle component analysis (PCA). Mutation analysis of KRAS, BRAF, PIK3CA and TP53 genes were performed by direct DNA sequencing. Correlation between the biological information, clinicopathological factors and clinical outcomes were analyzed.

2014-01-01 | E-GEOD-33193 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data